Skip to main content
. 2022 Oct 26;13:1023983. doi: 10.3389/fimmu.2022.1023983

Figure 3.

Figure 3

Patient survival for treatments with microwave ablation (MWA) in combination with apatinib and camrelizumab. Kaplan–Meier analysis of (A) progression-free survival (PFS) and (B) overall survival (OS).